SNSE vs. NBRV, APLT, PLUR, PRLD, MURA, ATNM, SCLX, GRCE, XCUR, and ACRV
Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), Exicure (XCUR), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry.
Sensei Biotherapeutics vs. Its Competitors
Sensei Biotherapeutics (NASDAQ:SNSE) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
Sensei Biotherapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sensei Biotherapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Sensei Biotherapeutics and 0 mentions for Nabriva Therapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Nabriva Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.
Sensei Biotherapeutics currently has a consensus target price of $90.00, suggesting a potential upside of 1,013.86%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Sensei Biotherapeutics is more favorable than Nabriva Therapeutics.
Sensei Biotherapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Sensei Biotherapeutics' return on equity of -66.72% beat Nabriva Therapeutics' return on equity.
Summary
Sensei Biotherapeutics beats Nabriva Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Sensei Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensei Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SNSE) was last updated on 7/15/2025 by MarketBeat.com Staff
Free SNSE Stock Alerts